Genentech's Prasinezumab Phase IIb Study Misses Primary Endpoint But Shows Potential In Early Parkinson's Disease

Benzinga · Dec 19 14:48

*– PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints –

– Prasinezumab continues to be well tolerated and no new safety signals were observed –

– Genentech is further evaluating the data and will work together with health authorities to determine next steps –

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

Genentech's Prasinezumab Phase IIb Study Misses Primary Endpoint But Shows Potential In Early Parkinson's Disease

Risk Disclaimer